MktsMarkets

Editas Medicine, Inc.
NASDAQ: EDITKey statistics
EDIT News
Stories mentioning EDIT from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 2,831 | 24,741 | 7,543 | 3,578 | 4,658 | 30,605 | 61.00 | 513.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 17,600 | 27,404 | 19,775 | 16,181 | 26,593 | 48,611 | 47,639 | 54,210 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 27,834 | 32,496 | 32,091 | 55,122 | 80,821 | 77,197 | 65,727 | 72,416 |
| Operating Income (Loss) | (25,003) | (7,755) | (24,548) | (51,544) | (76,163) | (46,592) | (65,666) | (71,903) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | (113.00) | (5.00) | (1.00) | (1,758) | (425.00) | (3.00) | (5.00) | (1.00) |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (24,982) | (5,620) | (25,117) | (53,235) | (76,088) | (45,395) | (62,141) | (67,607) |
| Earnings Per Share (Basic) | (0.26) | (0.06) | (0.28) | (0.63) | (0.92) | (0.55) | (0.75) | (0.82) |
| Earnings Per Share (Diluted) | (0.26) | (0.06) | (0.28) | (0.63) | (0.92) | (0.55) | (0.75) | (0.82) |
| Weighted Average Shares Outstanding (Basic) | 97,879 | 88,746 | 90,090 | 84,412 | 83,055 | 82,338 | 82,485 | 82,310 |
| Weighted Average Shares Outstanding (Diluted) | 97,879 | 88,746 | 90,090 | 84,412 | 83,055 | 82,338 | 82,485 | 82,310 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About EDIT
Editas Medicine, Inc. (NASDAQ: EDIT) is a stock listed on the Nasdaq Stock Market under the ticker symbol EDIT. It last traded at $2.17 (Nov 13, 2026, 9:30 AM ET), up 1.4% on the day. That gives Editas Medicine a market capitalisation of $334.9M.
Over the past 52 weeks EDIT has traded between $1.66 and $3.94.
Revenue for the quarter ended Mar 31, 2026 was $2.8M; a net loss of $25.0M. Revenue was down 39.2% from $4.7M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $2.8M | -$25.0M | -882.4% |
| Dec 31, 2025 | $24.7M | -$5.6M | -22.7% |
| Sep 30, 2025 | $7.5M | -$25.1M | -333.0% |
| Jun 30, 2025 | $3.6M | -$53.2M | -1487.8% |
From Editas Medicine’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…